Drug Profile

Alpibectir - BioVersys/GSK

Alternative Names: BVL-GSK-098; BVL-GSK3729098

Latest Information Update: 15 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BioVersys; GlaxoSmithKline
Developer BioVersys
Class Antituberculars; Fluorocarbons; Small molecules; Spiro compounds
Mechanism of Action Transcription factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Tuberculosis
New Molecular Entity Yes

Highest Development Phases

Phase II Tubercular meningitis; Tuberculosis

Most Recent Events

11 Dec 2025 BioVersys plans a phase II trial in meningeal Tuberculosis (PO), in 2026
27 Aug 2025 Alpibectir receives Orphan Drug status for Tuberculosis (Combination therapy) in European Union
03 Mar 2025 BioVersys initiates a phase II trial for Tuberculosis (Newly diagnosed, Combination therapy) (PO) (NCT06748937)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com